KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EBITDA: 2010-2025

Historic EBITDA for TherapeuticsMD (TXMD) over the last 15 years, with Sep 2025 value amounting to -$862,000.

  • TherapeuticsMD's EBITDA rose 23.99% to -$862,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year increase of 70.95%. This contributed to the annual value of -$4.8 million for FY2024, which is 53.69% up from last year.
  • TherapeuticsMD's EBITDA amounted to -$862,000 in Q3 2025, which was down 24.03% from -$695,000 recorded in Q2 2025.
  • Over the past 5 years, TherapeuticsMD's EBITDA peaked at $112.3 million during Q2 2022, and registered a low of -$49.0 million during Q1 2022.
  • Moreover, its 3-year median value for EBITDA was -$1.1 million (2024), whereas its average is -$1.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 363.25% in 2022, then slumped by 102.15% in 2023.
  • Quarterly analysis of 5 years shows TherapeuticsMD's EBITDA stood at -$43.0 million in 2021, then skyrocketed by 280.87% to $77.7 million in 2022, then plummeted by 101.14% to -$883,000 in 2023, then spiked by 179.28% to $700,000 in 2024, then grew by 23.99% to -$862,000 in 2025.
  • Its EBITDA stands at -$862,000 for Q3 2025, versus -$695,000 for Q2 2025 and -$871,000 for Q1 2025.